Melbourne, Australia, 17 October 2022: Certa Therapeutics,a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.
This year’s BIO-Europe Convention will be attended by Certa Therapeutics Chief Executive Officer, Professor Darren Kelly and Chief Commercial Officer, Dr Gareth Lewis.
BIO-Europe® is scheduled to take place 24 – 26 October 2022 in Leipzig, Germany and represents more than 3500 attendees, 110 presenting companies, from over 60 countries.
The Certa Therapeutics team will highlight their scientific advancements in anti-inflammatory and anti-fibrotic therapies, including their clinical development progress and plans with its novel therapeutic platform.
Certa Therapeutics has designed a platform of candidate drugs and validated the role of a novel receptor which mediates signalling pathways associated with inflammation and fibrosis. These targeted drugs have established proof of concept as potential treatments for multiple fibrotic diseases including serious and chronic conditions impacting the kidney, lung, heart eye, and skin. The morbidity and mortality impact of fibrotic diseases is substantial, ultimately causing 45% of all deaths globally. Certa Therapeutics is seeking to combine these innovative therapeutics with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment
The company’s most advanced molecule drug candidate, FT011, is being developed as a first-in-class oral therapy for the treatment for both scleroderma and chronic kidney disease.
This conference will allow the Certa Therapeutics team to engage and network with BIO-Europe members who are focused on the research and development plus commercialisation of innovative healthcare and biotechnology products.
BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision-makers from the biotechnology, pharmaceutical and financial sectors, offering private, prescheduled one-to-one meetings, as well as workshops and panels, company presentations, and showcasing companies and sponsors in the exhibition.
Come and meet with us in person to discuss our broad clinical research pipeline focused on precision therapies for chronic and rare diseases.
Or please email us at firstname.lastname@example.org